The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate

Journal of Bone and Mineral Research

Volumn 28, Issue 7, 2013, Pages 1653-1665

  Kumar, Sanjay ^a   Hoffman, Sandra J ^a   Samadfam, Rana ^b   Mansell, Peter ^b   Jolette, Jacquelin ^b   Smith, Susan Y ^b   Guldberg, Robert E ^c   Fitzpatrick, Lorraine A ^a  

^a GLAXOSMITHKLINE   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

BONE DENSITY; BONE HISTOMORPHOMETRY; BONE LOSS; BONE STRENGTH; OVARIECTOMIZED RAT; ROSIGLITAZONE; THIAZOLIDINEDIONE

Indexed keywords

ALENDRONIC ACID; DEOXYPYRIDINOLINE; PROCOLLAGEN C PROTEINASE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE FRAGILITY; BONE MASS; BONE MINERAL; BONE STRENGTH; BONE STRUCTURE; BONE TURNOVER; COMBINATION CHEMOTHERAPY; COMPRESSION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORTICAL BONE; DIAPHYSIS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; FEMALE; FEMUR; GEOMETRY; LUMBAR SPINE; MAXIMUM PLASMA CONCENTRATION; METAPHYSIS; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRABECULAR BONE; TREATMENT WITHDRAWAL; YOUNG MODULUS;

ALENDRONATE; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; TIME FACTORS; X-RAY MICROTOMOGRAPHY;

EID: 84879209262     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1918     Document Type: Article

References (35)

1. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G., Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008; 31: 845-51.
2. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP., Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2008; 93: 1696-701.
3. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR., Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009; 32: 187-202.
4. Douglas IJ, Evans SJ, Pocock S, Smeeth L., The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLoS Med. 2009; 6: e1000154.
5. Schwartz A., TZDs and bone: a review of the recent clinical evidence. PPAR Res [Internet]. 2008 [cited 2013 Mar 6];2008:297893. Available from: http://www.hindawi.com/journals/ppar/2008/297893.
6. Beresford JN, Bennett JH, Devlin C, Leboy PS, Owen ME., Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci. 1992; 102 (Pt 2): 341-51.
7. Nuttall ME, Gimble JM., Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis?. Bone. 2000; 27: 177-84.
8. Rosen ED., The transcriptional basis of adipocyte development. Prostaglandins Leukot Essent Fatty Acids. 2005; 73: 31-4.
9. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC., Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol. 1996; 50: 1087-94.
10. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B., Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 2004; 145: 401-6.
11. Samadfam R, Awori M, Benardeau A, Bauss F, Sebokova E, Wright M, Smith SY., Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats. J Endocrinol. 2012; 212: 179-86.
12. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL., Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005; 146: 1226-35.
13. Soroceanu MA, Miao D, Bai XY, Su H, Goltzman D, Karaplis AC., Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol. 2004; 183: 203-16.
14. Mbalaviele G, Abu-Amer Y, Meng A, Jaiswal R, Beck S, Pittenger MF, Thiede MA, Marshak DR., Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem. 2000; 275: 14388-93.
15. Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, Takeuchi Y., Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology. 1999; 140: 5060-5.
16. Schwab AM, Granholm S, Persson E, Wilkes B, Lerner UH, Conaway HH., Stimulation of resorption in cultured mouse calvarial bones by thiazolidinediones. Endocrinology. 2005; 146: 4349-61.
17. Li M, Amizuka N, Takeuchi K, Maeda T., Histochemical examination on the osteoclastic function on the microenvironment of extracellular matrices in osteolytic metastasis. J Bone Miner Res. 2005; 20: S167-8.
18. Sottile V, Seuwen K, Kneissel M., Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int. 2004; 75: 329-37.
19. Wan Y, Chong LW, Evans RM., PPAR-gamma regulates osteoclastogenesis in mice. Nat Med. 2007; 13: 1496-503.
20. Lazarenko OP, Rzonca SO, Suva LJ, Lecka-Czernik B., Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone. 2006; 38: 74-84.
21. Tornvig L, Mosekilde LI, Justesen J, Falk E, Kassem M., Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int. 2001; 69: 46-50.
22. Lecka-Czernik B, Lazarenko O, Teng K, Suva L., Activation of PPAR-gamma by rosiglitazone induces bone loss due to changes in the phenotype and function of bone mesenchymal cells. Second Joint Meeting of ECTS/IBMS, June 25-29, 2005, Geneva, Switzerland. MIS 2005 (2569163):P559-Su.
23. Shibata T, Takeuchi S, Yokota S, Kakimoto K, Yonemori F, Wakitani K., Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol. 2000; 130: 495-504.
24. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B., Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 2007; 148: 2669-80.
25. Bilezikian JP., Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med. 2009; 122: S14-21.
26. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R., Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010; 25: 1468-86.
27. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR., Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987 Dec; 2 (6): 595-610.
28. Benvenuti S, Cellai I, Luciani P, Deledda C, Baglioni S, Giuliani C, Saccardi R, Mazzanti B, Dal Pozzo S, Mannucci E, Peri A, Serio M., Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest. 2007; 30: RC26-30.
29. Sardone LD, Renlund R, Willett TL, Fantus IG, Grynpas MD., Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis. Diabetes. 2011; 60: 3271-8.
30. Lecka-Czernik B, Suva LJ., Resolving the two "bony" faces of PPAR-gamma. PPAR Res [Internet]. 2006 [cited 2013 Mar 6];2006:27489. Available from: http://www.hindawi.com/journals/ppar/2006/027489/abs/.
31. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ., Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373: 2125-35.
32. Borges JL, Bilezikian JP, Jones-Leone AR, Acusta AP, Ambery PD, Nino AJ, Grosse M, Fitzpatrick LA, Cobitz AR., A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients. Diabetes Obes Metab. 2011; 13: 1036-46.
33. Viberti G, Lachin J, Holman R, Zinman B, Haffner S, Kravitz B, Heise MA, Jones NP, O'Neill MC, Freed MI, Kahn SE, Herman WH., A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. Diabet Med. 2006; 23: 1289-94.
34. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR., The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007; 92: 1305-10.
35. Moseley KF., Type 2 diabetes and bone fractures. Curr Opin Endocrinol Diabetes Obes. 2012; 19: 128-35.